These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25613965)

  • 41. GAVI and the Vaccine Fund--a boon for immunization in the developing world.
    Balaji KA
    Indian J Public Health; 2004; 48(2):45-8. PubMed ID: 15709583
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis.
    Sinha A; Levine O; Knoll MD; Muhib F; Lieu TA
    Lancet; 2007 Feb; 369(9559):389-96. PubMed ID: 17276779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Childhood vaccination: achievements and challenges.
    Ndumbe P
    Afr Health; 1996 Sep; 18(6):18-9. PubMed ID: 12291732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Australia's contribution to global immunisation.
    Ruff TA; Taylor K; Nolan T
    Aust N Z J Public Health; 2012 Dec; 36(6):564-9. PubMed ID: 23216498
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance.
    Lee LA; Franzel L; Atwell J; Datta SD; Friberg IK; Goldie SJ; Reef SE; Schwalbe N; Simons E; Strebel PM; Sweet S; Suraratdecha C; Tam Y; Vynnycky E; Walker N; Walker DG; Hansen PM
    Vaccine; 2013 Apr; 31 Suppl 2():B61-72. PubMed ID: 23598494
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A global health partnership's use of time-limited support to catalyze health practice change: the case of GAVI's Injection Safety Support.
    Levin A; Fang A; Hansen PM; Pyle D; Dia O; Schwalbe N
    PLoS One; 2010 Sep; 5(9):e12986. PubMed ID: 20885995
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
    Atherly D; Dreibelbis R; Parashar UD; Levin C; Wecker J; Rheingans RD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S28-38. PubMed ID: 19817610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020.
    Gandhi G; Lydon P; Cornejo S; Brenzel L; Wrobel S; Chang H
    Vaccine; 2013 Apr; 31 Suppl 2():B137-48. PubMed ID: 23598475
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.
    Watson OJ; Barnsley G; Toor J; Hogan AB; Winskill P; Ghani AC
    Lancet Infect Dis; 2022 Sep; 22(9):1293-1302. PubMed ID: 35753318
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Domestic funding opportunities for Tanzania as five new Middle-Income countries brace for reduced Gavi support for immunization.
    Thomas Mori A; Christopher Bulula N; Magodi R; Mwengee W
    Vaccine; 2022 May; 40(24):3278-3285. PubMed ID: 35527062
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The decade of vaccines global vaccine action plan: shaping immunization programmes in the current decade.
    Cherian T; Okwo-Bele JM
    Expert Rev Vaccines; 2014 May; 13(5):573-5. PubMed ID: 24678869
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches.
    Watts E; Sim SY; Constenla D; Sriudomporn S; Brenzel L; Patenaude B
    Value Health; 2021 Jan; 24(1):78-85. PubMed ID: 33431157
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Shaping markets to benefit global health - A 15-year history and lessons learned from the pentavalent vaccine market.
    Malhame M; Baker E; Gandhi G; Jones A; Kalpaxis P; Iqbal R; Momeni Y; Nguyen A
    Vaccine X; 2019 Aug; 2():100033. PubMed ID: 31384748
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report.
    de Sanjosé S; Serrano B; Castellsagué X; Brotons M; Muñoz J; Bruni L; Bosch FX
    Vaccine; 2012 Nov; 30 Suppl 4():D1-83, vi. PubMed ID: 23510764
    [No Abstract]   [Full Text] [Related]  

  • 56. System within systems: challenges and opportunities for the Expanded Programme on Immunisation in Pakistan.
    Haq Z; Shaikh BT; Tran N; Hafeez A; Ghaffar A
    Health Res Policy Syst; 2019 May; 17(1):51. PubMed ID: 31101060
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Towards equity in immunisation.
    Boyce T; Gudorf A; de Kat C; Muscat M; Butler R; Habersaat KB
    Euro Surveill; 2019 Jan; 24(2):. PubMed ID: 30646979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccine Assistance To Low- And Middle-Income Countries Increased To $3.6 Billion In 2014.
    Haakenstad A; Birger M; Singh L; Liu P; Lim S; Ng M; Dieleman JL
    Health Aff (Millwood); 2016 Feb; 35(2):242-9. PubMed ID: 26858376
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Global routine vaccination coverage, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Oct; 59(42):1367-71. PubMed ID: 21030941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sustainable introduction of affordable new vaccines: the targeting strategy.
    Batson A
    Vaccine; 1998 Nov; 16 Suppl():S93-8. PubMed ID: 9915047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.